Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 11, 2025
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively –
Read more at globenewswire.com1.28
+0.06 (+4.92%)
Find more stocks in the Stock Screener
HOWL Latest News and Analysis
9 days ago - ChartmillTop movers in Tuesday's after hours sessionAs the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
